Transdermal Leader Tapemark specializes in transdermal and oral thin film drug delivery with end-to-end manufacturing, signaling strong potential for partnerships with pharma companies seeking integrated CDMO services to accelerate NDA/ANDA/505(b)(2) programs.

Full-Service Capability With formulation, coating, converting, packaging, and kitting under one roof, Tapemark can streamline development-to-commercialization for clients, offering a compelling value proposition for faster timelines and reduced supply chain complexity.

FDA Experience Significant track record in navigating FDA approvals including NDA, ANDA, and 505(b)(2), plus experience with Schedule I substances, positions Tapemark as a trusted partner for complex regulatory pathways and high-stakes launches.

Strategic Partnerships Recent collaborations with 10x Technology and LTS Lohmann Therapie-Systeme suggest a growth strategy through alliances to enhance transdermal solutions, presenting opportunities for co-development, co-investment, or capacity expansion collaborations.

Scale and Capability Operates a sizable 150,000-square-foot facility with a focus on owning equipment and rapid project management, indicating capacity readiness to take on additional client programs and larger scale transdermal/drug-film projects.